NEW YORK (GenomeWeb) – GIMDx announced today that it has signed an exclusive distribution agreement for IncellDx's single-cell immune-oncology and oncology diagnostic products in China.
Under the terms of the agreement, GIMDx will supply its China-based parent company Guangzhou Improve Medical Instruments with IncellDx component products, which will be kitted and co-labeled for the Chinese in vitro diagnostic market.
Included in the deal are IncellDx's single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes, its single-cell assay for HPV E6/E7 mRNA detection in cervical samples, and its IncellPrep single-cell preparation kit for solid tissues including tumors.
Additional terms were not disclosed.
Early in 2017, InCellDx received CE-IVD marking from European regulators, as well as US Food and Drug Administration IVD Class I status for the IncellPrep single-cell preparation kit for solid tissues.